No. As of October 2026, ViroGates A/S (VIRO.CO) is classified as DOUBTFUL by Musaffa under its AAOIFI-based Shariah screening methodology. ViroGates A/S does not fully pass Musaffa's business and financial screening criteria.
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
ViroGates A/S VIRO.CO
Last Updated: Oct 09, 12:00 AM·FNDK
VIRO.CO Shariah Compliance
Screening Methodology: AAOIFI
As of October 2026, ViroGates A/S is classified as doubtful.
Denmark Health Care Nano Cap